Your shopping cart is currently empty

CI-930 is a PDE-III inhibitor with broad-spectrum activity. It exerts its anti-aggregation effects through a dual mechanism: enhancing cAMP levels and selectively inhibiting the synthesis of TXA2 in platelets. CI-930 effectively inhibits platelet aggregation induced by AA, U-46619, ADP, collagen, and PAF, with IC50 values of 0.91, 0.73, 2.12, 2.35, and 7.15 mumols/L, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
| Description | CI-930 is a PDE-III inhibitor with broad-spectrum activity. It exerts its anti-aggregation effects through a dual mechanism: enhancing cAMP levels and selectively inhibiting the synthesis of TXA2 in platelets. CI-930 effectively inhibits platelet aggregation induced by AA, U-46619, ADP, collagen, and PAF, with IC50 values of 0.91, 0.73, 2.12, 2.35, and 7.15 mumols/L, respectively. |
| Synonyms | CI930, CI 930 |
| Molecular Weight | 254.29 |
| Formula | C14H14N4O |
| Cas No. | 86798-59-6 |
| Smiles | O=C1NN=C(C=2C=CC(=CC2)N3C=NC=C3)C(C)C1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.